Financhill
Sell
17

SYRS Quote, Financials, Valuation and Earnings

Last price:
$0.21
Seasonality move :
-16.53%
Day range:
$0.21 - $0.23
52-week range:
$0.18 - $7.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.81x
P/B ratio:
9.66x
Volume:
1.1M
Avg. volume:
2.9M
1-year change:
-96.89%
Market cap:
$5.9M
Revenue:
$9.9M
EPS (TTM):
-$3.07

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Syros Pharmaceuticals has 355.79% upside to fair value with a price target of -- per share.

SYRS vs. S&P 500

  • Over the past 5 trading days, Syros Pharmaceuticals has underperformed the S&P 500 by -2.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Syros Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Syros Pharmaceuticals revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Syros Pharmaceuticals reported revenues of --.

Earnings Growth

  • Syros Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Syros Pharmaceuticals reported earnings per share of -$0.16.
Enterprise value:
-11.3M
EV / Invested capital:
--
Price / LTM sales:
0.81x
EV / EBIT:
--
EV / Revenue:
-1.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $23.4M $8.8M -- $3.8M --
Gross Profit -- -- -- -- --
Operating Income -$115.8M -$135.5M -$111.5M -$32.3M -$26.2M
EBITDA -$106.9M -$97.4M -$91.1M -$38.2M -$4.8M
Diluted EPS -$16.38 -$3.82 -$3.07 -$1.43 -$0.16
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $98.6M $153.3M $252.3M $122.5M $63.9M
Total Assets $133.3M $208M $284.7M $147.8M $85M
Current Liabilities $28.1M $29.9M $38.4M $28.4M $28.4M
Total Liabilities $87.4M $102M $155.6M $111.5M $96.1M
Total Equity $45.9M $106.1M $129.2M $36.3M -$11.1M
Total Debt $19.7M $40.1M $40.5M $41.1M --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$115M -$122.2M -$100M -$31.9M -$20.7M
Cash From Investing $29.2M $73.5M $1.9M $28.6M --
Cash From Financing $141.8M -$10.6M $43.2M -$5K --
Free Cash Flow -$115.8M -$123.1M -$100M -$31.9M -$20.7M
SYRS
Sector
Market Cap
$5.9M
$44.7M
Price % of 52-Week High
--
51.72%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-96.89%
-33.41%
Beta (5-Year)
1.310
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $0.22
200-day SMA
Sell
Level $3.15
Bollinger Bands (100)
Sell
Level 0.32 - 2.16
Chaikin Money Flow
Sell
Level -148.7M
20-day SMA
Sell
Level $0.22
Relative Strength Index (RSI14)
Sell
Level 37.85
ADX Line
Sell
Level 15.72
Williams %R
Neutral
Level -77.7682
50-day SMA
Sell
Level $0.53
MACD (12, 26)
Sell
Level -0.07
25-day Aroon Oscillator
Buy
Level 24
On Balance Volume
Neutral
Level 340.8M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-7.4982)
Sell
CA Score (Annual)
Level (-4.6197)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.5441)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Stock Forecast FAQ

In the current month, SYRS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SYRS average analyst price target in the past 3 months is --.

  • Where Will Syros Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Syros Pharmaceuticals share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Syros Pharmaceuticals?

    Analysts are divided on their view about Syros Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Syros Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.

  • What Is Syros Pharmaceuticals's Price Target?

    The price target for Syros Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SYRS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Syros Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of SYRS?

    You can purchase shares of Syros Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Syros Pharmaceuticals shares.

  • What Is The Syros Pharmaceuticals Share Price Today?

    Syros Pharmaceuticals was last trading at $0.21 per share. This represents the most recent stock quote for Syros Pharmaceuticals. Yesterday, Syros Pharmaceuticals closed at $0.22 per share.

  • How To Buy Syros Pharmaceuticals Stock Online?

    In order to purchase Syros Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Will Quantum Computing Disrupt NVIDIA?
Will Quantum Computing Disrupt NVIDIA?

Earlier this month, NVIDIA CEO Jensen Huang seemingly dashed the…

What Trump Presidency Means For Stock Market
What Trump Presidency Means For Stock Market

Donald Trump was the first president in modern U.S. history…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
59
NUKK alert for Jan 21

Nukkleus [NUKK] is up 7.25% over the past day.

Sell
45
QMCO alert for Jan 21

Quantum [QMCO] is up 14.36% over the past day.

Buy
51
QRVO alert for Jan 21

Qorvo [QRVO] is up 3.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock